TELA Bio (TELA) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

TELA Stock Forecast


TELA Bio stock forecast is as follows: an average price target of $8.00 (represents a 179.72% upside from TELA’s last price of $2.86) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

TELA Price Target


The average price target for TELA Bio (TELA) is $8.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $8.00. This represents a potential 179.72% upside from TELA's last price of $2.86.

TELA Analyst Ratings


Buy

According to 2 Wall Street analysts, TELA Bio's rating consensus is 'Buy'. The analyst rating breakdown for TELA stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

TELA Bio Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 04, 2024Frank TakkinenLake Street$8.00$2.52217.46%179.72%
Aug 13, 2024Matt O'BrienPiper Sandler$8.00$4.0199.50%179.72%
May 22, 2024Kyle RoseCanaccord Genuity$14.00$6.20125.81%389.51%
May 10, 2024Matt O'BrienPiper Sandler$10.00$5.7873.01%249.65%
Nov 10, 2022JMP Securities$20.00$8.10146.91%599.30%
Nov 09, 2022Matt O'BrienPiper Sandler$15.00$6.50130.77%424.48%

The latest TELA Bio stock forecast, released on Oct 04, 2024 by Frank Takkinen from Lake Street, set a price target of $8.00, which represents a 217.46% increase from the stock price at the time of the forecast ($2.52), and a 179.72% increase from TELA last price ($2.86).

TELA Bio Price Target by Period


1M3M12M
# Anlaysts-14
Avg Price Target-$8.00$10.00
Last Closing Price$2.86$2.86$2.86
Upside/Downside-100.00%179.72%249.65%

In the current month, the average price target of TELA Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to TELA Bio's last price of $2.86. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 23, 2024Piper SandlerOverweightOverweightHold
Oct 04, 2024Piper SandlerMarket OutperformMarket OutperformHold
Oct 04, 2024Lake StreetUnderperformUnderperformHold
Oct 04, 2024Lake StreetBuyBuyHold
Oct 04, 2024Canaccord GenuityBuyBuyHold
Aug 13, 2024Piper SandlerOverweightOverweightHold
May 22, 2024Canaccord GenuityBuyBuyHold
May 10, 2024Piper SandlerOverweightOverweightHold
Nov 09, 2022Piper SandlerOverweightOverweightHold

TELA Bio's last stock rating was published by Piper Sandler on Oct 23, 2024. The company gave TELA a "Overweight" rating, the same as its previous rate.

TELA Bio Financial Forecast


TELA Bio Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$17.00M$15.05M$14.49M$11.91M$11.62M$11.16M$10.41M$8.23M$8.37M$7.65M$7.56M$5.88M$5.67M$5.31M$3.51M$3.73M$4.86M$3.97M
Avg Forecast$34.35M$30.12M$26.84M$25.41M$26.74M$23.73M$22.27M$21.05M$23.19M$18.85M$18.45M$16.32M$16.46M$16.20M$14.39M$12.01M$13.18M$10.86M$10.12M$7.94M$7.97M$7.55M$6.31M$5.46M$5.81M$4.57M$1.94M$3.66M$4.17M$3.94M
High Forecast$35.18M$30.85M$27.48M$26.02M$27.39M$24.30M$22.80M$21.56M$23.68M$18.89M$18.45M$16.32M$16.71M$16.20M$14.74M$12.30M$13.50M$10.86M$10.12M$7.94M$7.97M$7.55M$6.31M$5.46M$5.81M$4.57M$1.94M$3.66M$4.17M$3.94M
Low Forecast$33.81M$29.65M$26.42M$25.01M$26.32M$23.36M$21.92M$20.72M$22.69M$18.80M$18.45M$16.32M$16.21M$16.20M$14.17M$11.83M$12.98M$10.86M$10.12M$7.94M$7.97M$7.55M$6.31M$5.46M$5.81M$4.57M$1.94M$3.66M$4.17M$3.94M
# Analysts111111123111311111111111111111
Surprise %------------1.03%0.93%1.01%0.99%0.88%1.03%1.03%1.04%1.05%1.01%1.20%1.08%0.98%1.16%1.81%1.02%1.17%1.01%

TELA Bio's average Quarter revenue forecast for Mar 24 based on 1 analysts is $16.32M, with a low forecast of $16.32M, and a high forecast of $16.32M. TELA's average Quarter revenue forecast represents a -4.00% decrease compared to the company's last Quarter revenue of $17.00M (Dec 23).

TELA Bio EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111123111311111111111111111
EBITDA------------$-12.12M$-9.62M$-9.49M$-10.78M$-8.80M$-9.48M$-10.58M$-9.80M$-14.75M$-7.22M$-7.26M$-7.11M$-6.75M$-6.67M$-5.08M$-6.21M$-5.50M$-3.62M
Avg Forecast$-31.79M$-27.88M$-24.84M$-23.51M$-24.75M$-21.96M$-20.61M$-19.48M$-21.46M$-17.44M$-17.07M$-15.10M$-15.23M$-15.00M$-13.32M$-11.12M$-12.20M$-10.17M$-9.48M$-5.00$-7.46M$-7.07M$-5.91M$-5.92M$-5.44M$-4.28M$-1.81M$-5.43M$-3.91M$-3.69M
High Forecast$-31.29M$-27.44M$-24.45M$-23.15M$-24.36M$-21.62M$-20.29M$-19.18M$-21.00M$-17.40M$-17.07M$-15.10M$-15.00M$-15.00M$-13.11M$-10.94M$-12.01M$-10.17M$-9.48M$-4.00$-7.46M$-7.07M$-5.91M$-4.74M$-5.44M$-4.28M$-1.81M$-4.35M$-3.91M$-3.69M
Low Forecast$-32.55M$-28.55M$-25.44M$-24.08M$-25.34M$-22.49M$-21.11M$-19.95M$-21.92M$-17.48M$-17.07M$-15.10M$-15.46M$-15.00M$-13.64M$-11.39M$-12.50M$-10.17M$-9.48M$-6.00$-7.46M$-7.07M$-5.91M$-7.11M$-5.44M$-4.28M$-1.81M$-6.52M$-3.91M$-3.69M
Surprise %------------0.80%0.64%0.71%0.97%0.72%0.93%1.12%1959400.00%1.98%1.02%1.23%1.20%1.24%1.56%2.80%1.14%1.41%0.98%

undefined analysts predict TELA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than TELA Bio's previous annual EBITDA (undefined) of $NaN.

TELA Bio Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111123111311111111111111111
Net Income------------$-12.89M$-10.96M$-10.79M$-14.05M$-9.77M$-11.94M$-13.35M$-11.88M$-2.35M$-8.27M$-8.26M$-8.14M$-7.79M$-7.70M$-6.08M$-7.22M$-6.53M$-4.67M
Avg Forecast$-953.56K$-1.22M$-1.38M$-1.89M$-3.15M$-4.08M$-4.01M$-4.88M$-5.25M$-10.00M$-11.28M$-12.07M$-11.01M$-11.88M$-12.90M$-13.52M$-13.16M$-14.72M$-14.91M$-5.00$-12.86M$-12.78M$-12.69M$-6.78M$-11.85M$-11.90M$-14.61M$-6.32M$-14.67M$-13.81M
High Forecast$-934.29K$-1.20M$-1.35M$-1.85M$-3.09M$-3.99M$-3.93M$-4.78M$-3.65M$-9.80M$-11.05M$-11.83M$-10.51M$-11.64M$-12.64M$-13.24M$-12.90M$-14.72M$-14.91M$-4.00$-12.86M$-12.78M$-12.69M$-5.42M$-11.85M$-11.90M$-14.61M$-5.05M$-14.67M$-13.81M
Low Forecast$-983.50K$-1.26M$-1.42M$-1.95M$-3.25M$-4.20M$-4.14M$-5.03M$-6.62M$-10.31M$-11.63M$-12.45M$-11.26M$-12.25M$-13.30M$-13.94M$-13.58M$-14.72M$-14.91M$-7.00$-12.86M$-12.78M$-12.69M$-8.14M$-11.85M$-11.90M$-14.61M$-7.58M$-14.67M$-13.81M
Surprise %------------1.17%0.92%0.84%1.04%0.74%0.81%0.90%2376000.00%0.18%0.65%0.65%1.20%0.66%0.65%0.42%1.14%0.45%0.34%

TELA Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TELA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

TELA Bio SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111123111311111111111111111
SG&A------------$21.22M$18.20M$18.05M$17.10M$14.89M$14.70M$14.69M$12.84M$11.59M$10.41M$10.47M$9.05M$9.25M$8.95M$6.27M$7.79M$7.87M$5.94M
Avg Forecast$50.88M$44.62M$39.76M$37.64M$39.61M$35.15M$32.99M$31.18M$34.35M$27.92M$27.33M$24.17M$24.38M$24.01M$21.32M$17.80M$19.53M$16.09M$14.99M$6.00$11.80M$11.19M$9.35M$8.09M$8.60M$6.77M$2.87M$5.43M$6.18M$5.83M
High Forecast$52.11M$45.70M$40.72M$38.55M$40.57M$36.00M$33.78M$31.93M$35.09M$27.98M$27.33M$24.17M$24.75M$24.01M$21.84M$18.23M$20.00M$16.09M$14.99M$8.00$11.80M$11.19M$9.35M$8.09M$8.60M$6.77M$2.87M$5.43M$6.18M$5.83M
Low Forecast$50.09M$43.93M$39.14M$37.05M$39.00M$34.60M$32.47M$30.69M$33.61M$27.85M$27.33M$24.17M$24.02M$24.01M$20.99M$17.52M$19.23M$16.09M$14.99M$5.00$11.80M$11.19M$9.35M$8.09M$8.60M$6.77M$2.87M$5.43M$6.18M$5.83M
Surprise %------------0.87%0.76%0.85%0.96%0.76%0.91%0.98%2139333.33%0.98%0.93%1.12%1.12%1.07%1.32%2.19%1.44%1.27%1.02%

TELA Bio's average Quarter SG&A projection for Mar 24 is $24.17M, based on 1 Wall Street analysts, with a range of $24.17M to $24.17M. The forecast indicates a 13.94% rise compared to TELA last annual SG&A of $21.22M (Dec 23).

TELA Bio EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111123111311111111111111111
EPS------------$-0.53$-0.45$-0.46$-0.73$-0.51$-0.71$-0.92$-0.82$-0.16$-0.57$-0.57$-0.56$-0.54$-0.53$-0.53$-0.63$-1.22$-0.44
Avg Forecast$-0.04$-0.05$-0.06$-0.08$-0.13$-0.17$-0.16$-0.20$-0.21$-0.40$-0.46$-0.49$-0.45$-0.48$-0.52$-0.55$-0.53$-0.60$-0.60$-0.54$-0.52$-0.52$-0.51$-0.48$-0.48$-0.48$-0.59$-0.57$-0.59$-0.56
High Forecast$-0.04$-0.05$-0.05$-0.08$-0.12$-0.16$-0.16$-0.19$-0.15$-0.40$-0.45$-0.48$-0.43$-0.47$-0.51$-0.54$-0.52$-0.60$-0.60$-0.54$-0.52$-0.52$-0.51$-0.48$-0.48$-0.48$-0.59$-0.57$-0.59$-0.56
Low Forecast$-0.04$-0.05$-0.06$-0.08$-0.13$-0.17$-0.17$-0.20$-0.27$-0.42$-0.47$-0.50$-0.46$-0.50$-0.54$-0.56$-0.55$-0.60$-0.60$-0.54$-0.52$-0.52$-0.51$-0.48$-0.48$-0.48$-0.59$-0.57$-0.59$-0.56
Surprise %------------1.19%0.94%0.88%1.33%0.96%1.19%1.52%1.52%0.31%1.10%1.11%1.18%1.12%1.10%0.89%1.11%2.05%0.78%

According to undefined Wall Street analysts, TELA Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TELA previous annual EPS of $NaN (undefined).

TELA Bio Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
TELATELA Bio$2.86$8.00179.72%Buy
SGHTSight Sciences$3.55$7.50111.27%Hold
LUNGPulmonx$6.16$13.00111.04%Buy
RXSTRxSight$34.47$70.14103.48%Buy
DCTHDelcath Systems$11.34$22.0094.00%Buy
TMDXTransMedics Group$63.90$116.3382.05%Buy
KIDSOrthoPediatrics$22.58$39.5074.93%Buy
SIBNSI-BONE$13.27$18.5039.41%Buy
OFIXOrthofix Medical$17.34$24.0038.41%
NPCENeuroPace$11.14$15.0034.65%Buy
VREXVarex Imaging$14.71$17.0015.57%Buy
FNAParagon 28$10.27$11.5011.98%Buy
CVRXCVRx$12.90$14.2510.47%Buy
CLPTClearPoint Neuro$15.71$15.00-4.52%Buy
TCMDTactile Systems$17.33$16.00-7.67%Buy

TELA Forecast FAQ


Is TELA Bio a good buy?

Yes, according to 2 Wall Street analysts, TELA Bio (TELA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of TELA's total ratings.

What is TELA's price target?

TELA Bio (TELA) average price target is $8 with a range of $8 to $8, implying a 179.72% from its last price of $2.86. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will TELA Bio stock go up soon?

According to Wall Street analysts' prediction for TELA stock, the company can go up by 179.72% (from the last price of $2.86 to the average price target of $8), up by 179.72% based on the highest stock price target, and up by 179.72% based on the lowest stock price target.

Can TELA Bio stock reach $4?

TELA's average twelve months analyst stock price target of $8 supports the claim that TELA Bio can reach $4 in the near future.

What are TELA Bio's analysts' financial forecasts?

TELA Bio's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $93.78M (high $96.05M, low $92.32M), average EBITDA is $-86.79M (high $-85.441M, low $-88.887M), average net income is $-16.119M (high $-15.793M, low $-16.625M), average SG&A $138.93M (high $142.28M, low $136.77M), and average EPS is $-0.652 (high $-0.639, low $-0.673). TELA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $116.71M (high $119.53M, low $114.9M), average EBITDA is $-108M (high $-106M, low $-111M), average net income is $-5.446M (high $-5.336M, low $-5.617M), average SG&A $172.9M (high $177.07M, low $170.21M), and average EPS is $-0.22 (high $-0.216, low $-0.227).

Did the TELA's actual financial results beat the analysts' financial forecasts?

Based on TELA Bio's last annual report (Dec 2023), the company's revenue was $58.45M, which missed the average analysts forecast of $59.07M by -1.04%. Apple's EBITDA was $-44.075M, missing the average prediction of $-54.667M by -19.38%. The company's net income was $-46.664M, missing the average estimation of $-49.302M by -5.35%. Apple's SG&A was $74.57M, missing the average forecast of $87.51M by -14.78%. Lastly, the company's EPS was $-0.002, missing the average prediction of $-1.996 by -99.90%. In terms of the last quarterly report (Dec 2023), TELA Bio's revenue was $17M, beating the average analysts' forecast of $16.46M by 3.27%. The company's EBITDA was $-12.117M, missing the average prediction of $-15.233M by -20.45%. TELA Bio's net income was $-12.89M, beating the average estimation of $-11.009M by 17.08%. The company's SG&A was $21.22M, missing the average forecast of $24.38M by -12.99%. Lastly, the company's EPS was $-0.53, beating the average prediction of $-0.446 by 18.92%